Pulse Biosciences (PLSE)
(Delayed Data from NSDQ)
$12.05 USD
-0.57 (-4.52%)
Updated May 30, 2024 04:00 PM ET
After-Market: $11.97 -0.08 (-0.66%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PLSE 12.05 -0.57(-4.52%)
Will PLSE be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PLSE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PLSE
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
PLSE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Lags Revenue Estimates
Other News for PLSE
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
Pulse Biosciences announces updated timing of rights offering for up to $60M
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
Pulse Biosciences Stock: Signs Of Life Following Q1 Update
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session